CPC C07D 261/10 (2013.01) [A61K 31/4155 (2013.01); A61K 31/42 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 261/18 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); Y02A 50/30 (2018.01)] | 16 Claims |
1. A method of inhibiting HDAC, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of formula:
(Ia):
wherein A is selected from the group consisting of
—C(═O)NHheteroaryl, —NHC(═O)heteroaryl, aryl, heteroaryl, and
wherein B and C are, independently, aryl or heterocyclyl and n is 2 or 3;
or a pharmaceutically acceptable salt thereof; or
(Ib):
wherein A is selected from the group consisting
of, —NHC(═O)alkyl, —NHC(═O)cycloalkyl, —NHC(═O)heteroaryl, aryl, and heteroaryl; n is 0 or 1;
and p is 0 or 1; or a pharmaceutically acceptable salt thereof.
|